Image

North America Mycoplasma Testing in Clinical Market – Industry Trends and Forecast to 2027

  • In Vitro Diagnostics
  • Published Report
  • Oct 2020
  • North America
  • 350 Pages
  • No of Tables: 67
  • No of Figures: 36

North America Mycoplasma Testing in Clinical Market, By Products (Kits & Reagents, Instruments and Services), Techniques (Microbial Culture Techniques/Direct Assay, Polymerase Chain Reaction, ELISA, DNA Staining/Indirect Assay and Enzymatic Methods), Disease Area (Respiratory, Urogenital, Gastrointestinal, Musculoskeletal, Cardiovascular and Others), End User (Diagnostic Laboratories and Hospitals), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2027

North America Mycoplasma Testing in Clinical MarketMarket Analysis and Insights : North America Mycoplasma Testing in Clinical Market

Mycoplasma testing in clinical market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.8% in the forecast period of 2020 to 2027 and expected to reach USD 194.72 million by 2027.

Increase funding for diagnostics and increase in demand for fast and accurate testing are the major drivers which propelled the demand of the market in the forecast period. Mycoplasma testing in clinical market comprises features such as strategic initiatives by market players will impact in launching new product by the manufactures into the market which enhance its demand as well as increase in demand for fast and accurate testing has enhanced the demand of mycoplasma testing in clinical market.

Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and advanced mycoplasma testing in clinical which is expected to provide various other opportunities in the mycoplasma testing in clinical market. However, maintenance of instruments under proper storage conditions and long and laborious detection process are expected to restraint the market growth in the forecast period.

The mycoplasma testing in clinical market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Mycoplasma Testing in Clinical MarketMycoplasma Testing in Clinical Market Scope and Market Size

North America mycoplasma testing in clinical market is categorized into four notable segments which are based on products, techniques, disease area and end user. The growth among segments helps you to analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of products, the North America mycoplasma testing in clinical market is segmented into kits & reagents, instruments and services. In 2020, kits & reagents are expected to dominate in the market as these are mostly used for diagnosis of various types of mycoplasma associated disease.
  • On the basis of technique, the North America mycoplasma testing in clinical market is segmented into microbial culture techniques/direct assay, polymerase chain reaction, ELISA, DNA staining/indirect assay and enzymatic methods. In 2020, microbial culture techniques/direct assay are dominating the market because these are cost effective and provides with highly specified results.
  • On the basis of disease area, the North America mycoplasma testing in clinical market is segmented into respiratory, urogenital, gastrointestinal, musculoskeletal, cardiovascular and others. In 2020, respiratory segment is dominating the market because mycoplasma is known to cause pneumoniae to every age individuals involving children, young and adults.
  • On the basis of end user, the North America mycoplasma testing in clinical market is segmented into diagnostic laboratories and hospitals. In 2020, diagnostics laboratories segment is expected to dominate the market as diagnostics laboratories have well equipped diagnostic tools along with skilled professionals.

Mycoplasma Testing in Clinical Market Country Level Analysis

The mycoplasma testing in clinical market is analyzed and market size information is provided on the basis of the products, techniques, disease area, and end user.

The countries covered in the mycoplasma testing in clinical market report are the U.S., Canada, and Mexico.

The U.S. is dominating the North America market owing to increased healthcare funding. In North America region kits & reagents segment is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing mycoplasma testing in clinical field and research development for identification of mycoplasma cell culture contamination.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Number of Disease and Increase in Demand for Fast and Accurate Testing are Propelling the Market Growth

Mycoplasma testing in clinical market also provides you with detailed market analysis for every country growth in mycoplasma testing in clinical industry with mycoplasma testing in clinical sales, impact of advancement in the mycoplasma testing in clinical and changes in regulatory scenarios with their support for the mycoplasma testing in clinical market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Mycoplasma Testing in Clinical Market Share Analysis

Mycoplasma testing in clinical market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to mycoplasma testing in clinical market.

The major players covered in the report are bioMérieux SA, ELITechGroup, Liofilchem S.r.l., Agilent Technologies, Inc., PromoCell GmbH, F. Hoffmann-La Roche Ltd, Sacace Biotechnologies Srl, Lonza, Merck KGaA, Seegene Inc., Clongen Laboratories, LLC, Bio-Rad Laboratories, Inc., Charles River Laboratories and Bionique Testing Laboratories, Inc., among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch, approval, partnership and agreement are also initiated by the companies’ worldwide which also accelerating the mycoplasma are testing in clinical market.

For instance,

  • In June 2020, Liofilchem launched VTM (vital transport medium) for mycoplasma, virus, chlamydia, and ureaplasma. This product launch enhanced the company’s product portfolio for mycoplasma testing for clinical purpose.
  • In March 2019, Lonza introduced new luminometer which is designed to simplify and accelerate the testing procedure. This product introduction strengthened the company’s extensive product portfolio of mycoplasma detection used for clinical diagnosis purpose.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the mycoplasma testing in clinical market which also provides the benefit for organisation to improve their offering for mycoplasma testing in clinical.

Customization Available : North America Mycoplasma Testing in Clinical Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS 2019-2027 (USD MILLION)

TABLE 2 NORTH AMERICA KITS & REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION 2018-2027 (USD MILLION)

TABLE 3 NORTH AMERICA INSTRUMENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION 2018-2027 (USD MILLION)

TABLE 4 NORTH AMERICA SERVICES IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 5 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES, 2019-2027 (USD MILLION)

TABLE 6 NORTH AMERICA MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 7 NORTH AMERICA POLYMERASE CHAIN REACTION IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ELISA IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 NORTH AMERICA DNA STAINING/INDIRECT ASSAY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 NORTH AMERICA ENZYMATIC METHOD IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2019-2027 (USD MILLION)

TABLE 12 NORTH AMERICA RESPIRATORY MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 NORTH AMERICA TECHNIQUES IN RESPIRATORY MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2027 (USD MILLION)

TABLE 14 NORTH AMERICA UROGENITAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 15 NORTH AMERICA TECHNIQUES IN UROGENITAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2027 (USD MILLION)

TABLE 16 NORTH AMERICA GASTROINTESTINAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 NORTH AMERICA TECHNIQUES IN GSATROINTESTINAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2027 (USD MILLION)

TABLE 18 NORTH AMERICA CARDIOVASCULAR MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 19 NORTH AMERICA TECHNIQUES IN CARDIOVASCULAR MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2027 (USD MILLION)

TABLE 20 NORTH AMERICA MUSCULOSKELETAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 21 NORTH AMERICA TECHNIQUES IN MUSCULOSKELETAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2027 (USD MILLION)

TABLE 22 NORTH AMERICA OTHERS MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 NORTH AMERICA TECHNIQUES IN OTHERS MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2027 (USD MILLION)

TABLE 24 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 25 NORTH AMERICA DIAGNOSTIC LABORATORIES IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 26 NORTH AMERICA HOSPITALS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 27 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 28 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 29 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES, 2018-2027 (USD MILLION)

TABLE 30 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 31 NORTH AMERICA TECHNIQUES IN RESPIRATORY MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 32 NORTH AMERICA TECHNIQUES IN UROGENITAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 33 NORTH AMERICA TECHNIQUES IN GASTROINTESTINAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 34 NORTH AMERICA TECHNIQUES IN MUSCULOSKELETAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 35 NORTH AMERICA TECHNIQUES IN CARDIOVASCULAR MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 36 NORTH AMERICA TECHNIQUES IN OTHERS MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 37 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 38 U.S. MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2018-2027 (USD MILLION)

TABLE 39 U.S. MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES, 2018-2027 (USD MILLION)

TABLE 40 U.S. MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 41 U.S. TECHNIQUES IN RESPIRATORY MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 42 U.S. TECHNIQUES IN UROGENITAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 43 U.S. TECHNIQUES IN GASTROINTESTINAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 44 U.S. TECHNIQUES IN MUSCULOSKELETAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 45 U.S. TECHNIQUES IN CARDIOVASCULAR MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 46 U.S. TECHNIQUES IN OTHERS MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 47 U.S. MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 48 CANADA MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2018-2027 (USD MILLION)

TABLE 49 CANADA MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES, 2018-2027 (USD MILLION)

TABLE 50 CANADA MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 51 CANADA TECHNIQUES IN RESPIRATORY MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 52 CANADA TECHNIQUES IN UROGENITAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 53 CANADA TECHNIQUES IN GASTROINTESTINAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 54 CANADA TECHNIQUES IN MUSCULOSKELETAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 55 CANADA TECHNIQUES IN CARDIOVASCULAR MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 56 CANADA TECHNIQUES IN OTHERS MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 57 CANADA MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 58 MEXICO MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2018-2027 (USD MILLION)

TABLE 59 MEXICO MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES, 2018-2027 (USD MILLION)

TABLE 60 MEXICO MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 61 MEXICO TECHNIQUES IN RESPIRATORY MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 62 MEXICO TECHNIQUES IN UROGENITAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 63 MEXICO TECHNIQUES IN GASTROINTESTINAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 64 MEXICO TECHNIQUES IN MUSCULOSKELETAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 65 MEXICO TECHNIQUES IN CARDIOVASCULAR MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 66 MEXICO TECHNIQUES IN OTHERS MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 2018-2027 (USD MILLION)

TABLE 67 MEXICO MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions